![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TOXICOLOGY
-Aminobutyric Acid Type A Receptor Currents in Rat Cerebellar Granule and Cerebral Cortical Neurons in CultureNeuroscience Program and Department of Pharmacology/Toxicology, Michigan State University, East Lansing, Michigan
Cerebellar granule cells are particularly sensitive to inhibition by methylmercury (MeHg) on GABAA receptor function. This is manifested as a more rapid block of inhibitory postsynaptic currents/inhibitory postsynaptic potentials than for Purkinje cells. The underlying mechanism(s) for differential sensitivity of GABAergic transmission to MeHg in cerebellar neurons is unknown. Differential expression of
6 subunit-containing GABAA receptors in cerebellar granule and Purkinje neurons could partially explain this. GABA-evoked currents (IGABA) were recorded in response to MeHg in
6 subunit-containing cerebellar granule cells and
6 subunit-deficient cerebral cortical cells in culture. Cortical cells were substituted for Purkinje cells, which do not express
6 subunits. They express the same
1-containing GABAA receptor as Purkinje cells but lack characteristics that enhance Purkinje cell resistance to MeHg. IGABA were obtained using whole-cell recording and symmetrical [Cl–]. MeHg reduced IGABA to complete block in both cell types in a time- and concentration-dependent manner. This effect was faster in granule cells than cortical cells. Effects of MeHg on IGABA were recorded in granule cells at various developmental stages (days in vitro 4, 6, and 8) to alter the expression level of
6 subunit-containing GABAA receptors. Effects of MeHg on IGABA were similar in cells at all days. In human embryonic kidney 293 cells expressing either
6 or
1 subunit-containing GABAA receptors, time to block of IGABA by MeHg was comparable. Thus, the presence of the
6 subunit alone may not underlie the differential effects of MeHg on IGABA observed in cerebellar granule and cortical neurons; other factors are likely to be involved as well.
Address correspondence to: Dr. William D. Atchison, Department of Pharmacology and Toxicology, Michigan State University, B-331 Life Science Building, East Lansing, MI 48824-1317. E-mail: atchiso1{at}msu.edu